Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_2
1
20%
Ph phase_4
2
40%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)

Trials by Status

terminated120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study

NCT04580563
completedphase_2

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial

NCT03092245
completed

Observational Study of the Use of octaplasLG®.

NCT03369314
terminatedphase_4

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)

NCT02875236
completedphase_4

Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)

NCT02253082

Clinical Trials (5)

Showing 5 of 5 trials
NCT04580563Not Applicable

Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study

Completed
NCT03092245Phase 2

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial

Completed
NCT03369314

Observational Study of the Use of octaplasLG®.

Completed
NCT02875236Phase 4

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)

Terminated
NCT02253082Phase 4

Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5